Market news

Detailed price information for Dario Health Corp (DRIO-Q) from The Globe and Mail including charting and trades.

DarioHealth Corp (DRIO) reports improved gross margins and reduced losses while navigating a revenue dip from pharma exit and implementation timing.

Moby summary of DarioHealth Corp.'s Q2 2026 earnings call

At Yahoo Finance, you get free stock quotes, up-to-date news, portfolio management resources, international market data, social interaction and mortgage rates that help you manage your financial life.

DarioHealth (DRIO) delivered earnings and revenue surprises of +25.00% and -16.37%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Motley Fool Press Release.

DarioHealth Corp. (NASDAQ: DRIO) (the "Company", "DarioHealth" or "Dario"), a leading AI-powered healthcare technology company transforming the management of chronic conditions, today announced the launch of Dario's Integrated GLP-1 Program, the first commercial offering built on the Company's recently announced collaboration with Beluga Health ("Beluga").

DarioHealth (DRIO) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

DarioHealth Corp. (NASDAQ: DRIO) (the "Company," "DarioHealth" or "Dario"), a leading AI-powered healthcare technology company transforming the management of chronic conditions, today announced the Company expects broader deployment of DarioIQ™, its proprietary, responsible generative and agentic AI platform, to increase annual Business-to-Business-to-Consumer ("B2B2C") recurring revenue by approximately 10% to 15% from existing customers, before the impact of future customer wins or additional

DarioHealth Corp. (NASDAQ: DRIO) (the "Company", "DarioHealth" or "Dario"), a leader in global digital health, today announced a new agreement with a major health insurer with a stronghold in Arizona, entered into through its strategic channel partnership with Amwell. This opportunity makes Dario's cardiometabolic solution available to the insurer's Administrative Services Only ("ASO") book of business, representing access to hundreds of thousands of covered lives.